Medicine helps liver fat in transplant patients
Saroglitazar improves nonalcoholic fatty liver disease and metabolic health in liver transplant recipients
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A medicine called saroglitazar was given to people who had liver transplants and had fatty liver. After 24 weeks, their liver fat went down on average. The medicine didn’t hurt their muscles and was generally safe.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 532 / 44
Evidence Score
A snapshot of a population at a single point in time. Can identify correlations and prevalence, but cannot determine the direction of cause and effect.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
A medicine called saroglitazar was given to people who had liver transplants and had fatty liver. After 24 weeks, their liver fat went down on average. The medicine didn’t hurt their muscles and was generally safe.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 532 / 44
Evidence Score
A snapshot of a population at a single point in time. Can identify correlations and prevalence, but cannot determine the direction of cause and effect.
Publication
Authors
Siddiqui MS, Parmar D, Shaikh F, Forsgren M, Patel S, Bui AT, Boyett S, Patel V, Sanyal AJ
Related Content
Claims (6)
Excess visceral, liver, and intramuscular fat represent a serious metabolic dysfunction that is not solely due to lack of discipline, and reducing these fat depots improves metabolic function and overall well-being, with muscle quality being a key factor in longevity.
For people who had a liver transplant and have fatty liver disease, taking saroglitazar for 24 weeks lowered the amount of fat in their liver from about 10% to 8% on average. This finding is from the abstract summary - full study details were not available
About half of all patients and over 60% of those with higher initial liver fat saw their liver fat drop by at least 30% after taking saroglitazar for 24 weeks. This finding is from the abstract summary - full study details were not available
When liver transplant patients with fatty liver disease had lower levels of a liver enzyme called alkaline phosphatase after treatment, their liver fat also tended to decrease more. This finding is from the abstract summary - full study details were not available
Taking saroglitazar didn't make the muscles weaker or more fatty in liver transplant patients with fatty liver disease. This finding is from the abstract summary - full study details were not available